[DVA] DaVita Thesis 2026: Berkshire Stake Tests GLP-1 Long-Term Impact on Dialysis Demand
Key Takeaways
- FY2025 revenue ~$13-13.5B (+3-5% YoY) with adj. EPS ~$10.00-10.50 — DaVita Inc. is the largest US dialysis services provider serving ~200K+ patients across ~3,100 dialysis centers. FY2025 reflects continued Medicare reimbursement modest annual increases + selected patient census recovery + selected operational discipline + selected aggressive buyback program partially offset by selected labor cost inflation.
- 2 segments: US Dialysis ~85% + International ~15% — US Dialysis (~$11B revenue) dominant economic engine including
3,100 outpatient dialysis centers + selected hospital-based dialysis + selected home dialysis (peritoneal + home hemodialysis growing); International segment ($2-2.5B) includes selected international dialysis operations + selected Latin America. ~200K+ patient census selectively stable post-COVID excess deaths normalization. - CEO Javier Rodriguez since June 2019 — Rodriguez succeeded Kent Thiry. Rodriguez background: ex-DaVita Group President + selected operational background; ~25-year DaVita career. Rodriguez's tenure has executed: continued Medicare reimbursement engagement + selected operational excellence + aggressive capital return ($1-1.5B annual buybacks; ~5-7%/yr share count reduction) + selected international expansion. Berkshire Hathaway ~40%+ ownership stake (Buffett long-term holder; ~$3.5-4B Berkshire investment selected).
- FY2026 thesis tests three structural questions — (1) Berkshire Hathaway ownership signaling (~40%+ stake; selected long-term confidence); (2) GLP-1 weight-loss drug long-term impact on chronic kidney disease (CKD) progression + dialysis demand (selected potential 15-20% reduction in dialysis incidence over 10-15 years if GLP-1s slow CKD progression as suggested by selected clinical trials); (3) Aggressive capital return ($1-1.5B buybacks ~5-7%/yr share count reduction). Key risks: Medicare reimbursement (selected potential rate cuts under selected administration), GLP-1 long-term impact (~10-15 year lead time), labor costs (selected nursing wage inflation).
Company Background
DaVita Inc. (NYSE: DVA), founded 1979 as Total Renal Care + selected; rebranded DaVita 2000, is the largest US dialysis services provider. Headquartered in Denver, Colorado, DaVita operates ~3,100 dialysis centers serving ~200K+ patients globally. DaVita's competitive moat rests on three structural advantages: (1) selected scale + selected geographic dialysis center network — selected ~3,100 outpatient dialysis center network creates selected operational scale + selected payer negotiation power; (2) Medicare end-stage renal disease (ESRD) program — multi-decade selected Medicare ESRD program selected reimbursement structure provides selected stable demand for chronic dialysis services; (3) Berkshire Hathaway ownership signaling — Berkshire Hathaway ~40%+ ownership stake (Buffett long-term holder) provides selected capital markets credibility + selected long-term ownership stability.
CEO Javier Rodriguez took CEO role June 2019 (succeeded Kent Thiry CEO 1999-2019). Rodriguez's background:
- DaVita Group President (selected period; 2014-2019)
- Earlier DaVita operational + selected executive roles (~25-year career)
Rodriguez's tenure has executed:
- 2019-2020 Initial CEO Phase: continued operational excellence + selected
- 2020-2021 COVID Disruption: dialysis patients selected vulnerable to COVID-19; selected excess mortality affecting patient census FY2020-2022
- 2022-2024 Patient Census Recovery: selected post-COVID patient census stabilization + selected modest growth resuming
- 2023 DSI Renal Acquisition: $400M acquisition of selected dialysis services
- 2024-2025 Continued Discipline: continued operational excellence + aggressive capital return + selected international expansion
Rodriguez's strategic positioning emphasizes:
- US Dialysis operational excellence + selected patient census recovery
- Selected Medicare reimbursement engagement
- International expansion (selected emerging markets)
- Aggressive capital return (buybacks; no dividend)
- Selected operational discipline through Medicare reimbursement environment
Business Structure
DaVita reports operations across selected segments:
1. US Dialysis — ~$11B FY2025 (~85% of revenue):
- ~3,100 outpatient dialysis centers serving ~200K+ patients
- Selected hospital-based dialysis services
- Selected home dialysis (peritoneal + home hemodialysis growing — selected ~12-15% of patient census)
- Patient mix: Medicare ~70% + commercial 25% + Medicaid 5%
- Selected major US geographic coverage (selected ~50 states)
- Operating margin ~14-17%
2. International + Other — ~$2-2.5B FY2025 (~15% of revenue):
- Selected international dialysis operations (~10 countries)
- Selected Latin America + Asia + selected Europe
- Selected pharmacy + selected ancillary services
- Operating margin ~10-13%
Patient Mix:
- Medicare (US): 65-70% of US Dialysis revenue
- Commercial insurance: 22-26%
- Medicaid: 5-8%
- Selected international: ~15% of total
Berkshire Hathaway Ownership:
40%+ ownership stake ($3.5-4B Berkshire investment)- Buffett long-term holder (selected since selected 2011-2012 build-up)
- Selected long-term ownership stability + selected capital markets credibility
- Selected board influence
Key Core Metrics
Financial Performance Summary
| Metric | FY2022 | FY2023 | FY2024 | FY2025E |
|---|---|---|---|---|
| Revenue ($B) | 11.6 | 12.1 | 12.8 | 13-13.5 |
| Adj. EPS ($) | 6.79 | 7.81 | 9.40 | 10.00-10.50 |
| Operating margin (%) | 13 | 14 | 15 | 15-16 |
| FCF ($M) | 800 | 900 | 1,000 | 1,000-1,100 |
| Net debt ($B) | 8 | 8 | 8 | 8-9 |
| Diluted shares (M) | 95 | 90 | 85 | 83 |
| Annual dividend/share ($) | 0 | 0 | 0 | 0 |
Capital Return Framework (FY2025)
| Component | Annual ($M) | Per Share ($) |
|---|---|---|
| Dividend | 0 | 0 (no dividend) |
| Buybacks | ~1,000-1,500 | (~5-7%/yr share count reduction; aggressive) |
| Total capital return | ~1,000-1,500 |
Market Evaluation
DaVita Inc. trades at ~14-17x forward earnings with no dividend yield, reflecting dialysis services valuation framework where investors price near-term Medicare reimbursement + GLP-1 long-term impact + Berkshire stake + capital return into multiple. Bull case: Berkshire Hathaway ~40%+ stake provides selected long-term ownership confidence + aggressive buyback program ($1-1.5B/yr ~5-7%/yr share count reduction) compounds EPS through cycles + selected Medicare reimbursement environment manageable. Bear case: Medicare reimbursement (selected potential rate cuts under selected administration), GLP-1 long-term impact (selected potential 15-20% reduction in dialysis incidence over 10-15 years if GLP-1s slow CKD progression), labor costs (selected nursing wage inflation continuing).
Compared to peers: DVA vs Fresenius Medical Care (FMS, larger global dialysis ~$20B European-listed) — direct competitor + selected larger international scale; DVA vs Vantive Kidney Care (Carlyle Group acquired from Baxter November 2024 for $3.8B; selected dialysis products + selected dialysis services); DVA vs Diaverum (private European dialysis); DVA vs selected smaller regional dialysis providers. DaVita's selected scale + selected operational excellence + selected Medicare expertise + Berkshire ownership create structural competitive advantages.
Berkshire Stake + GLP-1 Impact + Capital Return
The FY2026 thesis for DaVita Inc. centers on Berkshire Hathaway ownership stake + GLP-1 long-term impact assessment + Medicare reimbursement + aggressive capital return.
Berkshire Hathaway Ownership Stake:
- ~40%+ ownership stake (Buffett long-term holder since 2011-2012 build-up)
- Selected ~$3.5-4B Berkshire investment value
- Selected long-term ownership stability + selected capital markets credibility
- Selected board influence (selected Berkshire-aligned director representation)
- Strategic significance: Berkshire long-term confidence signal + selected stability
GLP-1 Weight-Loss Drug Long-Term Impact:
- GLP-1 weight-loss drugs (Ozempic + Wegovy + Mounjaro + Zepbound + selected) demonstrating selected reduction in chronic kidney disease (CKD) progression in selected clinical trials
- Selected clinical evidence (FLOW trial 2024 + selected) showing semaglutide reduced kidney disease progression by 24% in CKD patients
- Long-term implications for dialysis demand:
- Short-term (1-5 years): minimal impact on existing dialysis patient census (~200K+ patients already on dialysis)
- Medium-term (5-15 years): potential 15-20% reduction in new dialysis incidence as GLP-1s slow CKD progression
- Long-term (15+ years): structural reduction in dialysis demand growth
- DaVita's strategic response: continued operational excellence + selected international expansion + selected aggressive capital return through near-term cash flow
Medicare Reimbursement:
- Medicare End-Stage Renal Disease (ESRD) program: selected primary payer for ~70% of DaVita US Dialysis revenue
- CMS annual rate increases: selected 2-3%/yr historical
- FY2024-2025 selected modest rate increases continuing
- Risk: selected potential rate cuts under selected administration policies
Aggressive Capital Return:
- Buybacks $1-1.5B FY2025 (~5-7%/yr share count reduction)
- Diluted shares trajectory: 95M FY2022 → 90M FY2023 → 85M FY2024 → 83M FY2025E (~13% reduction over 3 years)
- No dividend (selected aggressive buyback preferred)
- Net debt $8-9B
- Investment-grade Ba1/BB+ credit rating
FY2026 Outlook:
- Revenue toward $13.5-14B FY2026 (+3-5% on patient census + selected pricing)
- Adj. EPS toward $10.50-11.00 (+5-10% on operational leverage + buyback compounding)
- Operating margin sustained 15-16%
- FCF $1.0-1.2B
- Capital return $1.0-1.5B (buybacks; no dividend)
- Diluted shares toward 78-80M
- FY2027 outlook: revenue $14-14.5B, adj. EPS $11-12, capital return $1.0-1.5B
Key Risks:
- Medicare reimbursement (selected potential rate cuts under selected administration; selected ESRD program reform)
- GLP-1 long-term impact on dialysis demand (selected 10-15 year time horizon; selected structural reduction in dialysis incidence)
- Labor costs (selected nursing wage inflation continuing; selected workforce dynamics)
- Selected pharmaceutical reimbursement changes (selected dialysis-related medications)
- Selected commercial insurance pricing pressure
- Selected COVID-related continued patient census volatility
- Selected international expansion challenges
- Selected leverage concerns (~$8-9B net debt; selected refinancing exposure)
FY2026 Watch Items:
- Patient census trajectory (target +1-2% growth)
- Medicare CMS reimbursement rate (target 2-3% annual increase)
- Adj. EPS growth (target +5-10%)
- Capital return execution ($1-1.5B target)
- Operating margin trajectory (target 15-16%)
- GLP-1 clinical trial selected updates (selected long-term CKD progression data)
- Selected international expansion metrics
DaVita Inc.'s FY2026 thesis is Berkshire Hathaway ownership stake + Medicare reimbursement + GLP-1 long-term impact + aggressive capital return. Validation: patient census stable + Medicare manageable + buybacks delivered + Berkshire continues holding = thesis intact. Failure mode: Medicare rate cuts severe + GLP-1 impact accelerating earlier than expected + labor costs severe + Berkshire selling = dialysis services cycle compression DaVita cannot fully insulate against despite selected scale + Medicare expertise.